Oncopeptides selects OPSP-1 as first drug candidate from SPiKE platform
June 27, 2024
Oncopeptides AB has selected its first candidate drug based on the company’s unique platform for small polypeptide-based innate killer engagers (SPiKE). The SPiKE platform uses multispecific constructs, able to bind to multiple targets simultaneously.